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Conclusion: new parameters were found as predictors of 
moderate-severe mucositis. 
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Purpose or Objective: Retrospective review of results of 
radiotherapy for stage T1 glottic carcinoma. 
 
Material and Methods: A retrospective review was done of 
all patients with squamous cell carcinoma of the glottis stage 
T1 treated with radiotherapy between 1960 and 2012 
inclusive. There were 995 patients identified. All patients 
were treated with wedged lateral or angled anterior oblique 
technique. The main site of relapse was local and hence the 
main end point for anaysis was local control at 5 years. 
Survival curves were calculated using Kaplan Meier method 
and log rank test used to comparer differences. 
 
Results: Overall the 5 year freedom from relapse was 88%. 
The only factor which influenced outcome was time period of 
radiotherapy with those between 1960 and 1980 had a 84% 
relapse free rate, significantly worse than the latter time 
period. Other factors examined included sex, age, substage 
T1a and T1b, grade, radiation dose, radiation field size and 
duration of radiation, and none of those factors had a 
significant effect on outcome. There were 121 relapses, most 
in the primary alone and most within the first two years.  
 
Conclusion: The overall 5 year freedom from relapse was 
88%. 
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Purpose or Objective: To correlate clinical late dysphagia 
with the dose received by the constrictor pharyngeal muscles 
in patients receiving induction chemotherapy (ICT) and 
radiochemotherapy (RT-CT) with SIB-VMAT technique. 
 
Material and Methods: Between July 2010 and January 2015, 
51 patients with locally advanced head and neck cancer 
underwent ICT and subsequent RT-CT with concurrent weekly 
Cisplatin. The superior, middle, and inferior (S, M, and I) 
pharyngeal constrictors muscles (CM) were delineated and 
the correlation between dosimetric parameters and late 
pharyngeal toxicity was analyzed. 
 
Results: 51 patients [M/F: 41/10, median age 56, range 30-
77, stage III: 10 (20%), stage IV: 41 (80 %)] were included in 
this analysis. The tumor site was: oropharynx in 21 (40%) 
patients, epipharynx in 10 (20%), oral cavity in 9 (18%), larynx 
in 5 (10%), and hypopharynx in 6 (12%). ICT in the majority of 
cases (74%), was based on Cisplatin - 5 -Fluorouracil, with the 
addition of Docetaxel in 26% of cases. The dose delivered to 
the primary tumor was 67.5 Gy (in 8 patients, 16 %) and 70.5 
Gy (in 43 patients, 84 %); 60 Gy and 55.5 Gy were delivered 
on high and low risk lymph node levels, in 30 fractions with 
SIB-VMAT (2 arcs) technique, respectively. With a median 
follow-up of 11 months (range 3-44), late G1 dysphagia was 
recorded in 6 patients (12%) and late G2 dysphagia was 
observed in 2 patients (4%) (CTC-AE v. 4.3). Other late 
toxicities are reported in the Table 1. G3-4 toxicities were 
not recorded. In DVH analysis, the median dose received by 
CM was 66.2 Gy (S: 67.4 Gy, M and I: 67.2 Gy), with V50 being 
96.9 % (S: 97.4%, M: 98.3%, and I: 95.9 %), and V60 being 
82.4% (S: 86.8%, M: 90.1 %, and I: 73.8%). The median dose 
received by the larynx was 63.5 Gy (V50: 94.1 %, and V60: 
66.2 %). No statistically significant difference between the 
group of patients with and without late dysphagia was 
observed. 
 
 
 
Conclusion: No statistically significant correlation between 
dose delivered to the constrictors muscles and late dysphagia 
was observed in this patients cohort. This result may depend 
on tolerability of the treatment and then by the small 
number of recorded adverse events. 
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Purpose or Objective: To evaluate the toxicity of intensity 
modulated radio-chemotherapy with simultaneous integrated 
boost technique (SIB) after induction chemotherapy in 
patients with locally advanced head and neck (H&N) cancer. 
 
Material and Methods: The IRMA studies are described in the 
table. Patients with stage III-IV H&N cancer, without 
progressive disease after induction chemotherapy (IC), 
underwent radio-chemotherapy with weekly Cisplatin 30 
